Methadone Abuse And Statistics
An estimated 2 million individuals in the United States depend on or abuse opioids, consisting of heroin and prescription opioids such as oxycodone and hydrocodone.1 Withdrawal from these drugs is usually so intense that those who are dependent upon them continue taking the drugs in increasing doses to prevent withdrawal or to maintain the “high” produced by the drugs. Withdrawal signs may begin within 6 hours after the last heroin usage and might last for up to several months.2.
A reliable treatment for opioid reliance and addiction consists of medication-assisted therapy with the opioid medications methadone or buprenorphine, the only two opioids federally authorized for the treatment of these conditions. Methadone relieves cravings, blocks the blissful results associated with heroin and other opioids, and prevents withdrawal.3 Buprenorphine aids in treatment by avoiding symptoms of withdrawal.3.
Methadone, in usage given that 1964 for the treatment of opioid reliance, may be dispensed only in federally approved Opioid Treatment Programs (OTPs). Treatment protocols require that a client take the medication at the center where it is given daily.4 Take-home dosages are enabled just for clients who have actually been on a recognized maintenance program for a prolonged period of time.
In October 2002, buprenorphine was approved by the Food and Drug Administration (FDA) for the treatment of opioid dependence. Physicians who obtain specialized training may recommend buprenorphine. A few of these physicians remain in personal, office-based practices; others are affiliated with substance abuse treatment facilities or programs and may recommend buprenorphine to clients at those facilities. Additionally, OTPs might also recommend and/or dispense buprenorphine.
The National Study of Substance Abuse Treatment Services (N-SSATS), a yearly, national survey of all known substance abuse treatment facilities, both public and personal, offers details on the varieties of facilities that offer medication-assisted treatment with methadone and/or buprenorphine, in addition to on the varieties of customers receiving these medications. This report takes a look at the trends in making use of methadone and buprenorphine in the treatment of opioid reliance at substance abuse treatment facilities; it consists of data from OTPs along with facilities that did not have OTPs (hereafter described as “non-OTP facilities”). It does not include data from personal doctors who are not affiliated with a drug abuse treatment program or center.